List of Onsolis drug patents

Onsolis is owned by Bdsi.

Onsolis contains Fentanyl Citrate.

Onsolis has a total of 1 drug patent out of which 0 drug patents have expired.

Onsolis was authorised for market use on 16 July, 2009.

Onsolis is available in film;buccal dosage forms.

Onsolis can be used as management of breakthrough pain in patients with cancer.

The generics of Onsolis are possible to be released after 23 July, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597288 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 16 July, 2009

Treatment: Management of breakthrough pain in patients with cancer

Dosage: FILM;BUCCAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic